转自：推广 一群怀揣好奇与梦想的留学生踏上了前往敷尔佳工业研学之旅。这座融合了现代科技与自然之美的工业 园区，如同一块磁石，深深吸引着每一位远道而来的学子。 开启敷尔佳美丽之门，留学生们立刻被品牌馆内的与自己不同的东方面孔雕塑所震撼。以"东方面孔"为 主题，敷尔佳通过3DMAPPING和投影融合的独特设计向同学们演绎了一出理念和传承相结合的品牌诞 生记。 走进生产车间和立体库，自动化设备精准无误地运作，每一环节都彰显着中国科技的深厚底蕴与前沿创 新。他们惊叹于中国在生物科技领域的飞速发展，更被这种将传统智慧与现代科技完美融合的理念所折 服。 在研学过程中，留学生们不仅亲眼见证了产品从原料到成品的神奇蜕变，还亲身体验了敷尔佳对于品质 控制的极致追求。从精密的检测仪器到严格的生产流程，每一个细节都透露出中国企业对科技创新的执 着与热爱。 这次研学经历，对留学生们而言，不仅是一次知识的盛宴，更是一次心灵的触动。他们纷纷表示，中国 的科技实力远超想象，敷尔佳的工业研学之旅让他们深刻感受到了中国科技的魅力与潜力。 来自柬埔寨的学生美娜也向敷尔佳的小伙伴们分享，自己经常在社交媒体上看到敷尔佳，敷尔佳对于留 学生来说也是很 ...

Company Overview - Shenzhen Weiqi Technology Co., Ltd. (Weiqi Technology) has been accepted for IPO on the Beijing Stock Exchange, with Guosen Securities as the sponsor [2] - Established in 2011, the company has a registered capital of 50 million yuan, focusing on the R&D, production, sales, and related services of cosmetic raw materials and finished products [2] Fundraising and Projects - The company aims to raise 366 million yuan through the IPO, which will be allocated to the construction of the Weiqi Health Industry Park project and the Weiqi Technology R&D Center project [2] Product and Innovation - As of the signing date of the prospectus, Weiqi Technology has 16 cosmetic raw materials approved by the National Medical Products Administration, including 7 innovative raw materials, ranking first in both total and innovative raw material approvals [3] - The company has entered the supply chain of well-known domestic and international brands such as Marubi and Procter & Gamble [3] Ownership Structure - Ding Wenfeng and Lai Yanmin are the actual controllers of Weiqi Technology, collectively holding 62.1% of the shares [4] - Ding Wenfeng directly holds 57.28% of the shares and indirectly controls an additional 1.27% through the employee stock ownership platform, Weijukang, totaling 58.55% [4] Management Background - Ding Wenfeng, aged 48, holds a doctoral degree and has extensive experience in drug research and development, having worked in various pharmaceutical companies before leading Weiqi Technology [4][7] Financial Performance - The company's revenue is projected to grow from 135 million yuan in 2022 to 248 million yuan in 2024, with net profits increasing from approximately 35.13 million yuan to 70.64 million yuan during the same period, indicating rapid growth [9]

Core Viewpoint - Harbin Fulejia Technology Co., Ltd. is demonstrating resilience and potential in the competitive medical beauty skincare market, focusing on precise consumer demand and diversified market expansion [2] Group 1: Market Performance - In 2024, Fulejia achieved operating revenue of 2.017 billion yuan, a year-on-year increase of 4.32% [2] - Online sales reached 1.108 billion yuan in 2024, growing by 20.03% year-on-year, with strong performance during promotional events [3] Group 2: R&D and Innovation - R&D expenses increased by 6.04% in 2024, with the number of R&D personnel growing by 114.81% [3] - The completion of a self-owned production base and the establishment of a Shanghai R&D center in 2024 signify a strengthened R&D capability [3] Group 3: Shareholder Returns and Strategic Adjustments - Fulejia announced its first dividend in May 2024, with plans for another before the Spring Festival in early 2025, aiming to enhance stock liquidity [4] - The company is optimizing sales channel structures and strengthening product pricing management for long-term sustainable development [4][5] Group 4: Competitive Advantage - The acquisition of Harbin Beixing Pharmaceutical Co., Ltd. has provided Fulejia with independent production capabilities, laying a solid foundation for long-term growth [5] - The company aims to leverage its comprehensive competitive advantages in R&D, products, branding, resources, and market to enhance its position in the medical beauty skincare sector [5]

Company Overview - Fulejia is a company engaged in the research, production, and sales of professional skin care products, with a strong market recognition and brand influence [5] - The company offers a diverse range of products, including medical devices and functional skin care products, covering various forms such as masks, serums, and lotions [5][6] - Fulejia has established a multi-channel sales strategy, combining online platforms like Tmall and Douyin with offline channels such as medical institutions and retail pharmacies [5][6] Financial Performance - In the reporting period, the company achieved operating revenue of 2,016,975,873.58 yuan, representing a year-on-year increase of 4.32% [6] - The net profit attributable to shareholders was 661,129,436.27 yuan, a decrease of 11.77% year-on-year, primarily due to increased sales promotion expenses [6] Business Model - The company employs a "sales-driven production" model to ensure supply-demand balance and cost efficiency [7] - Fulejia utilizes a combination of self-production, entrusted processing, and OEM production to meet market demands [8] - The sales strategy includes direct sales, distribution, and consignment through both online and offline channels [9] Industry Trends - The skin care product manufacturing industry is evolving, with increasing consumer demand for high-quality products [14] - The market for professional skin care products is expected to grow, with projections indicating a market size of 518.5 billion yuan by 2026 [14] Key Performance Drivers - Fulejia focuses on product innovation and marketing strategies to maintain competitiveness in the skin care market [15] - The company has launched various new products to meet diverse consumer needs, including whitening and anti-wrinkle masks [16] - Continuous investment in research and development is aimed at enhancing product supply capabilities and production efficiency [18][19] Research and Development - The company has established a collaborative R&D model, integrating internal and external resources to respond quickly to industry changes [19] - Fulejia has received multiple patents and is actively expanding its product line in medical devices [20]

哈尔滨敷尔佳科技股份有限公司 首次公开发行股票并在创业板上市发行公告 保荐人（主承销商）：中信证券股份有限公司 特别提示 哈尔滨敷尔佳科技股份有限公司（以下简称"敷尔佳"、"发行人"或"公 司"）根据《证券发行与承销管理办法》（证监会令【第 208 号】）（以下简称 "《管理办法》"）《首次公开发行股票注册管理办法》（证监会令【第 205 号】） （以下简称"《注册办法》"）《深圳证券交易所首次公开发行证券发行与承销 业务实施细则》（深证上〔2023〕100 号）（以下简称"《业务实施细则》"） 《深圳市场首次公开发行股票网上发行实施细则》（深证上〔2018〕279 号）（以 下简称"《网上发行实施细则》"）及《深圳市场首次公开发行股票网下发行实 施细则（2023 年修订）》（深证上〔2023〕110 号）（以下简称"《网下发行实 施细则》"）《首次公开发行证券承销业务规则》（中证协发〔2023〕18 号）（以 下简称"《承销业务规则》"）《首次公开发行证券网下投资者管理规则》（中 证协发〔2023〕19 号）（以下简称"《网下投资者管理规则》"）等相关法律法 规、监管规定及自律规则等文件，以及深圳证券交易所 ...